- Home
- CGNT vs CRVS Comparison
CGNT vs CRVS Comparison
Compare CGNT & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGNT
- CRVS
- Stock Information
- Founded
- CGNT 2020
- CRVS 2014
- Country
- CGNT Israel
- CRVS United States
- Employees
- CGNT N/A
- CRVS N/A
- Industry
- CGNT Computer Software: Prepackaged Software
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- CGNT Technology
- CRVS Health Care
- Exchange
- CGNT Nasdaq
- CRVS Nasdaq
- Market Cap
- CGNT 639.4M
- CRVS 516.0M
- IPO Year
- CGNT N/A
- CRVS 2016
- Fundamental
- Price
- CGNT $9.66
- CRVS $5.01
- Analyst Decision
- CGNT Hold
- CRVS Strong Buy
- Analyst Count
- CGNT 3
- CRVS 5
- Target Price
- CGNT $8.25
- CRVS $12.38
- AVG Volume (30 Days)
- CGNT 271.0K
- CRVS 1.6M
- Earning Date
- CGNT 12-11-2024
- CRVS 11-12-2024
- Dividend Yield
- CGNT N/A
- CRVS N/A
- EPS Growth
- CGNT N/A
- CRVS N/A
- EPS
- CGNT N/A
- CRVS N/A
- Revenue
- CGNT $339,818,000.00
- CRVS N/A
- Revenue This Year
- CGNT $13.67
- CRVS N/A
- Revenue Next Year
- CGNT $6.92
- CRVS N/A
- P/E Ratio
- CGNT N/A
- CRVS N/A
- Revenue Growth
- CGNT 12.16
- CRVS N/A
- 52 Week Low
- CGNT $5.68
- CRVS $1.30
- 52 Week High
- CGNT $9.97
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- CGNT 66.71
- CRVS 37.72
- Support Level
- CGNT $8.47
- CRVS $4.60
- Resistance Level
- CGNT $9.97
- CRVS $6.47
- Average True Range (ATR)
- CGNT 0.32
- CRVS 0.39
- MACD
- CGNT 0.06
- CRVS 0.03
- Stochastic Oscillator
- CGNT 79.33
- CRVS 21.93
About CGNT Cognyte Software Ltd.
Cognyte Software Ltd provides security analytics software that empowers governments and enterprises with Actionable Intelligence. Its interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).